Management of diabetic foot ulcers

Diabetes Therapy

Volumn 3, Issue 1, 2012, Pages 1-15

  Alexiadou, Kleopatra ^a   Doupis, John ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Salamis Naval Base   (Greece)

Author keywords

Debridement; Diabetic foot; Dressings; Neuropathy; Off loading; Pathogenesis; Peripheral arterial disease; Ulceration

Indexed keywords

ALGINIC ACID; BECAPLERMIN; EPIDERMAL GROWTH FACTOR; GELATINASE A; GRANULOCYTE COLONY STIMULATING FACTOR; MATRIX METALLOPROTEINASE; PLACEBO; SCLEROPROTEIN;

ANKLE BRACHIAL INDEX; AWARENESS; CLINICAL ASSESSMENT; COST EFFECTIVENESS ANALYSIS; DEBRIDEMENT; DIABETIC FOOT; DIABETIC NEUROPATHY; DRUG MEGADOSE; EDUCATION; FOOT INJURY; HEALTH CARE ACCESS; HUMAN; HYPERBARIC OXYGEN; LIMB PERFUSION; MAGGOT THERAPY; MOTOR NEUROPATHY; PATHOGENESIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSICAL EXAMINATION; PREDICTIVE VALUE; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; RISK FACTOR; SCORING SYSTEM; SEX DIFFERENCE; SKIN EXAMINATION; SOCIAL ASPECT; SOCIAL STATUS; THROMBOCYTE RICH PLASMA; VACUUM ASSISTED CLOSURE; WALKING AID; WOUND DRESSING;

EID: 84861882779     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-012-0004-9     Document Type: Review

References (85)

1. Abbott CA, Carrington AL, Ashe H, North-West Diabetes Foot Care Study, et al. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med. 2002;19:377-84.
2. Centers for Disease Control and Prevention. Lower extremity disease among persons aged ≥40 years with and without diabetes-United States, 1999-2002. MMWR Morb Mortal Wkly Rep. 2005;54:1158-60.
3. Lauterbach S, Kostev K, Kohlmann T. Prevalence of diabetic foot syndrome and its risk factors in the UK. J Wound Care. 2010;19:333-7.
4. Katsilambros N, Dounis E, Makrilakis K, Tentolouris N, Tsapogas P. Atlas of the diabetic foot. 2nd ed. Oxford: Wiley-Blackwell; 2010.
5. Moxey PW, Gogalniceanu P, Hinchliffe RJ, et al. Lower extremity amputations-a review of global variability in incidence. Diabet Med. 2011;28:1144-53.
6. Lavery LA, Armstrong DG, Vela SA, Quebedeaux TL, Fleischli JG. Practical criteria for screening patients at high risk for diabetic foot ulceration. Arch Intern Med. 1998;158:157-62.
7. Malgrange D, Richard JL, Leymarie F, French Working Group On The Diabetic Foot. Screening diabetic patients at risk for foot ulceration. A multicentre hospital-based study in France. Diabetes Metab. 2003;29:261-8.
8. Prompers L, Huijberts M, Schaper N, et al. Resource utilisation and costs associated with the treatment of diabetic foot ulcers. Prospective data from the Eurodiale Study. Diabetologia. 2008;51:1826-34.
9. Kumar S, Ashe HA, Parnell LN, et al. The prevalence of foot ulceration and its correlates in type 2 diabetic patients: a population-based study. Diabet Med. 1994;11:480-4.
10. Tesfaye S, Stevens LK, Stephenson JM, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia. 1996;39:1377-84.
11. Brem H, Sheehan P, Boulton AJ. Protocol for treatment of diabetic foot ulcers. Am J Surg. 2004;187:1S-10S.
12. Bowering CK. Diabetic foot ulcers. Pathophysiology, assessment, and therapy. Can Fam Physician. 2001;47:1007-16.
13. Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). Eur J Vasc Endovasc Surg. 2000;19(Suppl. A):S1-250.
14. Prompers L, Huijberts M, Apelqvist J, et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia. 2007;50:18-25.
15. Boulton AJ. The diabetic foot-an update. Foot Ankle Surg. 2008;14:120-4.
16. Benotmane A, Mohammedi F, Ayad F, Kadi K, Azzouz A. Diabetic foot lesions: etiologic and prognostic factors. Diabetes Metab. 2000;26:113-7.
17. Hoffman AF. Evaluation of arterial blood flow in the lower extremity. Clin Podiatr Med Surg. 1992;9:19-56.
18. Puttemans T, Nemery C. Diabetes: the use of color Doppler sonography for the assessment of vascular complications. Eur J Ultrasound. 1998;7:15-22.
19. Williams DT, Harding KG, Price P. An evaluation of the efficacy of methods used in screening for lowerlimb arterial disease in diabetes. Diabetes Care. 2005;28:2206-10.
20. Kravitz SR, McGuire J, Shanahan SD. Physical assessment of the diabetic foot. Adv Skin Wound Care. 2003;16:68-75.
21. Papanas N, Papatheodorou K, Papazoglou D, Kotsiou S, Maltezos E. Association between foot temperature and sudomotor dysfunction in type 2 diabetes. J Diabetes Sci Technol. 2010;4:803-7.
22. Armstrong DG, Holtz-Neiderer K, Wendel C, Mohler MJ, Kimbriel HR, Lavery LA. Skin temperature monitoring reduces the risk for diabetic foot ulceration in high-risk patients. Am J Med. 2007;120:1042-6.
23. Meijer JW, Smit AJ, Sonderen EV, Groothoff JW, Eisma WH, Links TP. Symptom scoring systems to diagnose distal polyneuropathy in diabetes: the Diabetic Neuropathy Symptom score. Diabet Med. 2002;19:962-5.
24. Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med. 2004;21:976-82.
25. Boulton AJ, Armstrong DG, Albert SF, American Diabetes Association; American Association of Clinical Endocrinologists, et al. Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care. 2008;31: 1679-85.
26. Perkins BA, Orszag A, Ngo M, Ng E, New P, Bril V. Prediction of incident diabetic neuropathy using the monofilament examination: a 4-year prospective study. Diabetes Care. 2010;33:1549-54.
27. Schaper NC. Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. Diabetes Metab Res Rev. 2004;20(Suppl. 1):S90-5.
28. Doupis J, Veves A. Classification, diagnosis, and treatment of diabetic foot ulcers. Wounds. 2008;20:117-26.
29. Hinchliffe RJ, Valk GD, Apelqvist J, et al. Specific guidelines on wound and wound-bed management. Diabetes Metab Res Rev. 2008;24(Suppl. 1):S188-9.
30. Lebrun E, Tomic-Canic M, Kirsner RS. The role of surgical debridement in healing of diabetic foot ulcers. Wound Repair Regen. 2010;18:433-8.
31. Smith RG. Enzymatic debriding agents: an evaluation of the medical literature. Ostomy Wound Manage. 2008;54:16-34.
32. Margolin L, Gialanella P. Assessment of the antimicrobial properties of maggots. Int Wound J. 2010;7:202-4.
33. Hilton JR, Williams DT, Beuker B, Miller DR, Harding KG. Wound dressings in diabetic foot disease. Clin Infect Dis. 2004;39(Suppl. 2):S100-3.
34. Saap LJ, Falanga V. Debridement performance index and its correlation with complete closure of diabetic foot ulcers. Wound Repair Regen. 2002;10:354-9.
35. Game FL, Hinchliffe RJ, Apelqvist J, et al. A systematic review of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes Metab Res Rev. 2012;28(Suppl. 1):119-41.
36. Veves A, Murray HJ, Young MJ, Boulton AJ. The risk of foot ulceration in diabetic patients with high foot pressure: a prospective study. Diabetologia. 1992;35:660-3.
37. Pham H, Armstrong DG, Harvey C, Harkless LB, Giurini JM, Veves A. Screening techniques to identify people at high risk for diabetic foot ulceration: a prospective multicenter trial. Diabetes Care. 2000;23:606-11.
38. Frykberg RG, Lavery LA, Pham H, Harvey C, Harkless L, Veves A. Role of neuropathy and high foot pressures in diabetic foot ulceration. Diabetes Care. 1998;21:1714-9.
39. Pound N, Chipchase S, Treece K, Game F, Jeffcoate W. Ulcer-free survival following management of foot ulcers in diabetes. Diabet Med. 2005;22:1306-9.
40. Burns J, Begg L. Optimizing the offloading properties of the total contact cast for plantar foot ulceration. Diabet Med. 2011;28:179-85.
41. Cavanagh PR, Bus SA. Off-loading the diabetic foot for ulcer prevention and healing. J Vasc Surg. 2010;52(Suppl.):37S-43S.
42. Armstrong DG, Lavery LA, Wu S, Boulton AJ. Evaluation of removable and irremovable cast walkers in the healing of diabetic foot wounds: a randomized controlled trial. Diabetes Care. 2005;28:551-4.
43. Armstrong DG, Nguyen HC, Lavery LA, van Schie CH, Boulton AJ, Harkless LB. Off-loading the diabetic foot wound: a randomized clinical trial. Diabetes Care. 2001;24:1019-22.
44. Clark RAF. Wound repair: overview and general considerations. In: Clark RAF, editor. The molecular and cellular basis of wound repair. New York: Plenum Press; 1996. p. 3-50.
45. Harding KG, Jones V, Price P. Topical treatment: which dressing to choose. Diabetes Metab Res Rev. 2000;16(Suppl. 1):S47-50.
46. Olson ME, Wright JB, Lam K, Burrell RE. Healing of porcine donor sites covered with silver-coated dressings. Eur J Surg. 2000;166:486-9.
47. Tredget EE, Shankowsky HA, Groeneveld A, Burrell R. A matched-pair, randomized study evaluating the efficacy and safety of Acticoat silver-coated dressing for the treatment of burn wounds. J Burn Care Rehabil. 1998;19:531-7.
48. Papanas N, Maltezos E. Benefit-risk assessment of becaplermin in the treatment of diabetic foot ulcers. Drug Saf. 2010;33:455-61.
49. Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. J Vasc Surg. 1995;21:71-8 (discussion 79-81).
50. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled doubleblind study. Diabetes Care. 1998;21:822-7.
51. US Food and Drugs Administration. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm072148.htm. Accessed Dec 23, 2011.
52. Yang HS, Shin J, Bhang SH, et al. Enhanced skin wound healing by a sustained release of growth factors contained in platelet-rich plasma. Exp Mol Med. 2011;43:622-9.
53. Margolis DJ, Kantor J, Santanna J, Strom BL, Berlin JA. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. Diabetes Care. 2001;24:483-8.
54. Driver VR, Hanft J, Fylling CP, Beriou JM, AutologelDiabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous plateletrich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manage. 2006;52:68-70, 72, 74 passim.
55. Cruciani M, Lipsky BA, Mengoli C, de Lalla F. Granulocyte-colony stimulating factors as adjunctive therapy for diabetic foot infections. Cochrane Database Syst Rev. 2009;(8):CD006810.
56. Huang P, Li S, Han M, Xiao Z, Yang R, Han ZC. Autologous transplantation of granulocyte colonystimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemiain diabetes. Diabetes Care. 2005;28: 2155-60.
57. de Lalla F, Pellizzer G, Strazzabosco M, et al. Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threateningdiabetic foot infection. Antimicrob Agents Chemother. 2001;45:1094-8.
58. Ycheönem A, Cakir B, Güler S, Azal OO, Corakçi A. Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection. Diabetes Obes Metab. 2001;3:332-7.
59. Uchi H, Igarashi A, Urabe K, et al. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. Eur J Dermatol. 2009;19:461-8.
60. Richard JL, Parer-Richard C, Daures JP, et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. A pilot, randomized, double-blind, placebocontrolled study. Diabetes Care. 1995;18:64-9.
61. Tuyet HL, Nguyen Quynh TT, Vo Hoang Minh H, et al. The efficacy and safety of epidermal growth factor in treatment of diabetic foot ulcers: thepreliminary results. Int Wound J. 2009;6:159-66.
62. Tsang MW, Wong WK, Hung CS, et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care. 2003;26:1856-61.
63. Edmonds M, Bates M, Doxford M, Gough A, Foster A. New treatments in ulcer healing and wound infection. Diabetes Metab Res Rev. 2000;16(Suppl. 1):S51-4.
64. Ehrenreich M, Ruszczak Z. Update on tissueengineered biological dressings. Tissue Eng. 2006;12:2407-24.
65. Uccioli L, Giurato L, Ruotolo V, et al. Two-step autologous grafting using HYAFF scaffolds in treating difficult diabetic foot ulcers: results of a multicenter, randomized controlled clinical trial with long-term follow-up. Int J Low Extrem Wounds. 2011;10:80-5.
66. Moustafa M, Simpson C, Glover M, et al. A new autologous keratinocyte dressing treatment for non-healing diabetic neuropathic foot ulcers. Diabet Med. 2004;21:786-9.
67. Niezgoda JA, Van Gils CC, Frykberg RG, Hodde JP. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers. Adv SkinWound Care. 2005;18:258-66.
68. Martin BR, Sangalang M, Wu S, Armstrong DG. Outcomes of allogenic acellular matrix therapy in treatment of diabetic foot wounds: an initial experience. Int Wound J. 2005;2:161-5.
69. Mansbridge J. Skin substitutes to enhance wound healing. Expert Opin Investig Drugs. 1998;7:803-9.
70. Caravaggi C, De Giglio R, Pritelli C, et al. HYAFF 11-based autologous dermal and epidermal grafts in the treatment of noninfected diabetic plantar and dorsal foot ulcers: a prospective, multicenter, controlled, randomized clinical trial. Diabetes Care. 2003;26:2853-9.
71. Veves A, Sheehan P, Pham HT. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg. 2002;137:822-7.
72. Karim RB, Brito BL, Dutrieux RP, Lassance FP, Hage JJ. MMP-2 assessment as an indicator of wound healing: a feasibility study. Adv Skin Wound Care. 2006;19:324-7.
73. Pirayesh A, Dessy LA, Rogge FJ, et al. The efficacy of a polyhydrated ionogen impregnated dressing in the treatment of recalcitrant diabetic foot ulcers: a multicentre pilot study. Acta Chir Belg. 2007;107:675-81.
74. Xie X, McGregor M, Dendukuri N. The clinical effectiveness of negative pressure wound therapy: a systematic review. J Wound Care. 2010;19:490-5.
75. McCallon SK, Knight CA, Valiulus JP, Cunningham MW, McCulloch JM, Farinas LP. Vacuum-assisted closure versus saline-moistened gauze in the healing of postoperative diabetic foot wounds. Ostomy Wound Manage. 2000;46(28-32): 34.
76. Eginton MT, Brown KR, Seabrook GR, Towne JB, Cambria RA. A prospective randomized evaluation of negative-pressure wound dressings for diabetic foot wounds. Ann Vasc Surg. 2003;17:645-9.
77. Armstrong DG, Diabetic Foot Study Consortium. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. Lancet. 2005;366:1704-10.
78. Broussard CL. Hyperbaric oxygenation and wound healing. J Vasc Nurs. 2004;22:42-8.
79. Kessler L, Bilbault P, Ortéga F, et al. Hyperbaric oxygenation accelerates the healing rate of nonischemic chronic diabetic foot ulcers: a prospective randomized study. Diabetes Care. 2003;26:2378-82.
80. Faglia E, Favales F, Aldeghi A, et al. Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer. A randomized study. Diabetes Care. 1996;19: 1338-43.
81. Tiaka EK, Papanas N, Manolakis AC, Maltezos E. The role of hyperbaric oxygen in the treatment of diabetic foot ulcers. Angiology. 2011 (Epub ahead of print).
82. Tan T, Shaw EJ, Siddiqui F, Kandaswamy P, Barry PW, Guideline Development Group. Inpatient management of diabetic foot problems: summary of NICE guidance. BMJ. 2011;342:d1280.
83. Hinchliffe RJ, Valk GD, Apelqvist J, et al. A systematic review of the effectiveness of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes Metab Res Rev. 2008;24(Suppl. 1):S119-44.
84. Larsson J, Apelqvist J, Agardh CD, Stenström A. Decreasing incidence of major amputation in diabetic patients: a consequence of a multidisciplinary foot care team approach? Diabet Med. 1995;12:770-6.
85. Lavery LA, Wunderlich RP, Tredwell JL. Disease management for the diabetic foot: effectiveness of a diabetic foot prevention program to reduce amputations and hospitalizations. Diabetes Res Clin Pract. 2005;70:31-7.